Sciendo Logo
  1. bookVolume 51 (2017): Issue 2 (June 2017)
Radiology and Oncology's Cover Image
Radiology and Oncology
Journal Details
License
Format
Journal
First Published
30 Apr 2007
Publication timeframe
4 times per year
Languages
English
access type Open Access

Dosimetric predictors of treatment-related lymphopenia induced by palliative radiotherapy: predictive ability of dose-volume parameters based on body surface contour

Tetsuo Saito
Ryo Toya
Tomohiko Matsuyama
Akiko Semba
Natsuo Oya
Published Online: 13 Oct 2016
Page range: 228 - 234
Received: 18 Jul 2016
Accepted: 30 Aug 2016
Journal Details
License
Format
Journal
First Published
30 Apr 2007
Publication timeframe
4 times per year
Languages
English
AbstractBackground

Radiation-related lymphopenia has been associated with poor patient outcome. Our aim was to identify predictors of lymphopenia after palliative radiotherapy, with a focus on dose-volume parameters.

Patients and methods

To retrospectively assess patients with various cancers who had undergone palliative radiotherapy, we delineated three organs at risk: the volume enclosed by the body surface contour (body A), the volume left after excluding air, pleural effusion, ascites, bile, urine, and intestinal content (body B), and the volume of the bone marrow (BM). We then noted the absolute volume of the three organs at risk that had received 5-30 Gy, and assessed the predictive value for post-treatment lymphopenia of grade 3 or higher (LP3+).

Results

Of 54 patients, 23 (43%) developed LP3+. Univariate logistic regression analysis showed that body A V5, body A V10, body B V5, body B V10, the number of fractions, and splenic irradiation were significant predictors of LP3+ (p < 0.05). By multivariate analysis, body A V5, body A V10, body B V5, body B V10, and the number of fractions retained significance (p < 0.05). BM dose-volume parameters did not predict lymphopenia.

Conclusions

Higher body A and body B dose-volume parameters and a larger number of fractions may be predictors of severe lymphopenia after palliative radiotherapy.

Key words

  • palliative radiotherapy
  • radiation-related lymphopenia
  • dose-volume parameters
Introduction

The important role of lymphocytes in the immune response to cancer1 is evidenced by the better survival of lung-, colorectal-, and breast cancer-, and glioblastoma patients whose cancer tissues manifest lymphocyte infiltration.2-5 Survival tends to be poor in cancer- and lymphoma patients with lymphopenia before undergoing treatment6-10, and treatment-related lymphopenia is associated with a poor outcome in patients subjected to curative chemoradiotherapy for pancreatic-, lung-, cervical-, and nasopharyngeal cancer and malignant glioma.11-18

The irradiation of circulating peripheral blood may elicit radiation-related lymphopenia.19,20 Although studies to evaluate the effect of irradiation on lymphocytes showed that radiation-related lymphopenia was associated with organ-specific (lung14 and brain21) dose-volume parameters, dosimetric predictors applicable at various treatment sites remained to be identified.

Radiation-related lymphopenia has been studied mainly in patients who had received curative treatment11-18; there are few reports on patients subjected to palliative radiotherapy (RT). Because lymphocytes are highly radiosensitive, exposure to even low doses of radiation can lead to a decrease in the number of peripheral blood lymphocytes.22,23 Consequently, even low radiation doses delivered by palliative RT can lead to lymphopenia affecting the immune system and the treatment outcome.

Focusing on dose-volume parameters, we attempted to identify predictors of lymphopenia after palliative RT. We used organs at risk based on body surface contour to evaluate their predictive value.

Patients and methods
Patients

This retrospective study was approved by the institutional review board of Kumamoto University Hospital (No. 1171). The study was carried out according to the Declaration of Helsinki. Our inclusion criteria were as follows: patients treated with palliative RT between October 2010 and June 2013 at the Kumamoto University Hospital; the availability of laboratory data acquired within 2 weeks prior to the start of RT; and of two or more laboratory data obtained within one month after the start of RT, the latest data recorded at least 2 weeks after the start of RT. The exclusion criteria were hematologic tumor; chemotherapy, molecular targeted therapy, interferon treatment, or radiotherapy delivered from one month before to one month after the start of RT; or grade 2 or higher lymphopenia based on the Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 at the start of RT. Patient-, tumor-, and treatment data were obtained from medical charts.

Laboratory data

The study endpoints were (1) the absolute lymphocyte count at nadir, defined as the lowest value recorded within one month after the start of RT, (2) the lymphocyte count ratio, obtained by dividing the nadir absolute lymphocyte count by the pre-RT absolute lymphocyte count, and (3) lymphopenia of grade 3 or higher (LP3+, absolute lymphocyte count < 500 × 106/L) determined by CTCAE v 4.0, with the highest grade within one month after the start of RT recorded for analysis.

Delineation of the three organs at risk. Body A is the volume enclosed by the body surface contour. Body B excludes air, pleural effusion, ascites, bile, urine, and the intestinal content. BM = bone marrow.

Dose-volume parameters

All patients underwent CT simulation in the supine position, and three-dimensional treatment planning. For this study, we delineated organs at risk on planning CT images with commercially available software (Velocity AI, Velocity Medical System, Atlanta, GA, USA). To evaluate the effect of radiation on peripheral blood lymphocytes, one radiation oncologist delineated the volume of two organs at risk where body A is the volume enclosed by the body surface contour, and body B is the volume left after excluding air, pleural effusion, ascites, bile, urine, and intestinal content (Figure 1). For body A, the body surface contour was obtained first by using threshold-based segmentation and then by manual correction. To obtain body B, we excluded volumes whose irradiation would not contribute to the reduction of lymphocytes; lung tissue was included and the trachea and bronchi were excluded. For bone marrow (BM), all bones were delineated by threshold-based segmentation and manual correction (Figure 1); intervertebral disks and costal-, thyroid-, cricoid-, and tracheal cartilage were excluded. The distal half of the femur and humerus were also excluded from BM because they contain little proliferating bone marrow.24 The absolute volumes of the three organs at risk receiving 5-, 10-, 20-, and 30 Gy (V5, V10, V20, and V30) were recorded.

Statistical analysis

Data were summarized by using descriptive statistics (frequency, percentage, median, range). The correlation between the dose-volume parameters and the nadir lymphocyte count was evaluated with the Spearman correlation coefficient. For univariate and multivariate logistic regression analysis, the age, interval from tumor diagnosis, the pre-RT absolute lymphocyte count, total radiation dose, number of fractions, total monitor units, total irradiation time, and all dose-volume parameters were the continuous variables. The categorical variables included the gender, previous RT, previous chemotherapy, concurrent steroid use, bone metastasis, brain metastasis, splenic irradiation, and thymic irradiation. Variables that were significant in univariate analysis were included in multivariate analysis. The overall survival, calculated from the start of RT, was estimated with the KaplanMeier method; differences determined with the log-rank test. Values of p < 0.05 were considered statistically significant. All statistical analyses were performed with SPSS software, version 23 (IBM SPSS, Armonk, NY, USA).

Results
Patients

We included 54 patients whose solid tumors were treated with palliative RT. The patient and treatment characteristics are summarized in Table 1. As we excluded patients with lymphopenia of grade 2 or higher (absolute lymphocyte count < 800 × 106/L), all included patients had a pre-RT absolute lymphocyte count > 800 × 106/L. The median follow-up period from the start of RT was 4.5 months (range 0−42.0 months).

Laboratory data

The median pre-RT absolute lymphocyte count was 1356 × 106/L (range 844-3468 × 106/L), and the median nadir post-RT absolute lymphocyte count was 536 × 106/L (range 131-1653 × 106/L). The median lymphocyte count ratio, obtained by dividing the nadir-by the pre-RT absolute lymphocyte count, was 0.410 (range 0.108-0.983). Of the 54 patients, 12 (22%), 19 (35%), 20 (37%), and 3 (6%) patients had post-treatment lymphopenia of grade 1, 2, 3, and 4, respectively; a total of 23 (43%) patients developed LP3+.

Dose-volume parameters

The median (range) V5, V10, V20, and V30 for body A were 2.880 (0.399-8.976), 2.519 (0.344-6.596), 1.629 (0.000-4.255), and 0.660 (0.000-3.365) × 103 mL, respectively. These values were 2.704 (0.3928.143), 2.384 (0.341-5.959), 1.597 (0.000-3.919), and 0.645 (0.000-3.326) × 103 mL for body B and 0.348 (0.000-0.974), 0.258 (0.000-0.909), 0.174 (0.0000.737), and 0.076 (0.000-0.724) × 103 mL for BM.

Correlation between the dose-volume parameters and the nadir lymphocyte count

There was a negative correlation between body dose-volume parameters (V5, V10, and V30 for body A and body B) and the nadir lymphocyte count (p < 0.05, Table 2). Higher body A and body B dose-volume parameters were correlated with a lower post-RT lymphocyte count. There was no significant correlation between BM dose-volume parameters and the nadir lymphocyte count (Table 2). We observed a strong correlation between body A V5 and body B V5 (Speaman’s rho = 0.992, p < 0.001), between body A V10 and body B V10 (Speaman’s rho = 0.992, p < 0.001), between body A V20 and body B V20 (Speaman’s rho = 0.997, p < 0.001), and between body A V30 and body B V30 (Speaman’s rho = 0.999, p < 0.001).

Patient and treatment characteristics (n = 54)

CharacteristicNo. of patients%
Patient characteristics
Male gender3361
Age (years)
 Median69
Range39-86
Primary tumor
 Lung1426
 Gastrointestinal917
 Skin47
 Liver36
 Uterus36
 Others

Others include head and neck (3 patients), breast (3 patients), mediastinal (3 patients), urogenita (8 patients), and soft tissue (4 patients) tumors;

2139
Previous radiotherapy1528
Previous chemotherapy2648
Concurrent steroid use2343
Bone metastasis2750
Brain metastasis1120
Interval from tumor diagnosis to radiotherapy (months)
 Median13
 Range0-168
Pre-radiotherapy absolute lymphocyte count (× 106/L)
 Median1356
 Range844-3468
Treatment characteristics
Total radiation dose (Gy)
 Median30
 Range16-50
Number of fractions
 Median10
 Range4-25
Fraction size (Gy)
 Median3
 Range2-5
Total monitor units for all fractions
 Median4433
 Range1896–13890
Total irradiation time for all fractions (minutes)
 Median7.5
 Range3.2-37.7
Treatment site
 Head and neck1426
 Chest2444
 Abdomen1019
 Pelvis1120
 Limb12
Splenic irradiation

Yes, if any part of the spleen was covered by the 5 Gy idodose line;

917
Thymic irradiation

Yes, if any part of the thymus was covered by the 5 Gy idodose line.

1528

Spearman correlation coefficients between the dose-volume parameters and the nadir lymphocyte count

Nadir lymphocyte count
Absolute lymphocyte count at nadirLymphocyte count ratio

The lymphocyte count ratio was calculated by dividing the nadir absolute lymphocyte count by the pre-radiotherapy absolute lymphocyte count.

VariableSpearman’s rhop-valueSpearman’s rhop-value
Body A V5-0.2650.053-0.3500.010
Body A V10-0.2830.038-0.3670.006
Body A V20-0.2310.093-0.2550.063
Body A V30-0.3050.025-0.2810.039
Body B V5-0.2740.045-0.3470.010
Body B V10-0.2800.040-0.3520.009
Body B V20-0.2360.086-0.2600.057
Body B V30-0.3020.027-0.2800.041
BM V5-0.1520.27-0.2100.13
BM V10-0.1610.25-0.2070.13
BM V20-0.1350.33-0.1610.25
BM V30-0.1680.23-0.1850.18

BM = bone marrow;

Overall survival according to the grade of radiationrelated lymphopenia.

CI = confidence interval.

Predictors of severe treatment-related lymphopenia

Univariate logistic regression analysis showed that body A V5, body A V10, body B V5, body B V10, the number of fractions, and splenic irradiation were significant predictors of LP3+ (p < 0.05, Table 3). For multivariate analysis, we took into account factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) to test the independent significance of dose-volume parameters (Table 4). We found that body A V5, body A V10, body B V5, body B V10, and the number of fractions retained significance (p < 0.05). Higher body A and body B dose-volume parameters and a larger number of fractions were predictive of LP3+.

Relationship between radiation-related lymphopenia and overall survival

The median survival for all patients was 6.3 months (95% confidence interval: 4.1–8.5 months). The overall survival based on the grade of radiation-related lymphopenia is shown in Figure 2. There was no statistically significant difference in the overall survival of patients with LP3+ and the other grades of lymphopenia (p = 0.79).

Discussion

We found that body A V5, body A V10, body B V5, body B V10, and the number of fractions were significant predictors of severe radiation-related lymphopenia. Higher body A and body B dose-volume parameters and a larger number of fractions were predictive of LP3+. In contrast, irradiation to lymphoid organs such as the bone marrow, spleen, and thymus were not predictive of radiation-related lymphopenia.

Others19,20 suggested that the irradiation of circulating peripheral blood may lead to the development of radiation-related lymphopenia. This hypothesis is supported by findings that lymphopenia was observed after the delivery of RT to various body parts that did, or did not, include lymphoid organs.19,25 The irradiation of extracorporeal blood can lead to long-lasting lymphopenia.26 Tang et al.14 found that in lung cancer patients, higher lung V5 to V10 values were associated with a lower lymphocyte nadir, and Huang et al.21 reported that in patients with high-grade glioma, higher brain volume receiving 25 Gy was a significant predictor of acute severe lymphopenia during RT and concurrent temozolomide. We document that the body dose-volume parameters we applied are useful predictors of lymphopenia in patients exposed to RT at different sites including the head and neck, the chest, abdomen, and the pelvis.

Our univariate and multivariate logistic regression analysis showed that irradiation to the bone marrow, spleen, and thymus was not a consistently significant predictor. Lymphoid organs such as the thymus, bone marrow, and spleen are central components of the mammalian immune system; lymphocytes are developed in these organs.27 While splenic irradiation was a significant predictor of LP3+ by univariate logistic regression analysis, it lost its significance upon multivariate analysis. Because the 95% confidence interval was wide in our multivariate analysis (Table 4), the predictive value of splenic irradiation should be examined in large patient populations. We detected no significant association between lymphopenia and bone marrow irradiation although Sini et al.28 reported that the exposure of bone marrow to radiation played a significant role. They found that higher BM V40 was associated with higher risk of acute Grade3 or late Grade2 lymphopenia in prostate cancer patients treated with whole-pelvis RT. Because information on the role of lymphoid organs in radiation-related lymphopenia is limited, additional studies are warranted.

The number of fractions was a significant predictor of severe radiation-related lymphopenia. This finding agrees with earlier observations.20,29 MacLennan et al.29 analyzed the consequences of prophylactic cranial irradiation in children with leukemia. In their prospective study, the total radiation dose was constant (24 Gy) and the number of fractions was determined by the participating centers. They found that the level of radiation-related lymphopenia induced by that total dose depended on the number of fractions into which it was divided. The mean lymphocyte count of patients examined 3 months after receiving this dose in 5-, 12-, and 20 fractions was 1.84-, 1.12-, and 0.64 × 109/L, respectively. Yovino et al.20 analyzed a model that calculated the radiation dose received by circulating lymphocytes; they found that as the number of fractions increased, the percentage of blood receiving > 0.5 Gy increased rapidly. We also found that the number of fractions was a significant predictor of radiation-related lymphopenia, however, in our study the total radiation dose was not a significant predictor. Because lymphocytes are highly radiosensitive22,23, their number killed by one fraction may not be strongly associated with the dose per fraction. A larger dose per fraction might be relatively less effective in killing lymphocytes than a small dose.

Univariate logistic regression analysis for lymphopenia of grade 3 or higher

VariableOR95% CIp-value
Patient characteristics
Male vs. female1.390.46–4.220.55
Age (per 1 year increase)0.990.94–1.030.53
Previous radiotherapy (yes vs. no)1.020.30–3.470.98
Previous chemotherapy (yes vs. no)0.530.18–1.580.26
Concurrent steroid use (yes vs. no)1.070.36–3.170.91
Bone metastasis (yes vs. no)0.860.29–2.530.78
Brain metastasis (yes vs. no)0.720.18–2.840.64
Interval from tumor diagnosis to radiotherapy (per 1 month increase)1.000.99–1.020.81
Pre-radiotherapy absolute lymphocyte count (per increase of 1 × 106/l)0.990.99–1.000.23
Treatment characteristics
Total radiation dose (per 1-Gy increase)1.060.99–1.140.11
Number of fractions (per 1-fraction increase)1.181.01–1.380.036
Total monitor units over the entire treatment
course (per increase of 100 monitor units)1.010.99–1.030.29
Total irradiation time over the entire treatment course (per 1-minute increase)0.990.92–1.080.91
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line

6.341.18–34.240.032
Thymic irradiation (yes vs. no)

Yes, if any part of the thymus was covered by the 5 Gy idodose line.

0.580.17–2.030.39
Body A V5 (per 1 × 103 mL increase)1.551.06–2.260.025
Body A V10 (per 1 × 103 mL increase)1.601.04–2.450.032
Body A V20 (per 1 × 103 mL increase)1.600.96–2.680.074
Body A V30 (per 1 × 103 mL increase)1.870.95–3.680.069
Body B V5 (per 1 × 103 mL increase)1.581.05–2.380.027
Body B V10 (per 1 × 103 mL increase)1.631.04–2.560.035
Body B V20 (per 1 × 103 mL increase)1.590.94–2.720.087
Body B V30 (per 1 × 103 mL increase)1.840.93–3.670.082
BM V5 (per 1 × 103 mL increase)3.620.37–35.360.27
BM V10 (per 1 × 103 mL increase)2.880.27–31.100.38
BM V20 (per 1 × 103 mL increase)1.780.15–20.920.65
BM V30 (per 1 × 103 mL increase)4.730.19–115.780.34

BM = bone marrow; OR = odds ratio; CI = confidence interval

Multivariate logistic regression analysis for lymphopenia of grade 3 or higher

VariableOR95% CIp-value
Body A V5 (per 1 × 103 mL increase)1.581.03–2.420.036
Number of fractions (per 1-fraction increase)1.261.03–1.530.027
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.120.74–35.280.098
Body A V10 (per 1 × 103 mL increase)1.681.04–2.700.034
Number of fractions (per 1-fraction increase)1.261.03–1.550.026
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.250.77–35.760.090
Body B V5 (per 1 × 103 mL increase)1.631.03–2.570.038
Number of fractions (per 1-fraction increase)1.251.03–1.530.028
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.460.79–37.530.085
Body B V10 (per 1 × 103 mL increase)1.721.04–2.870.036
Number of fractions (per 1-fraction increase)1.261.03–1.550.027
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.590.82–37.990.078

CI = confidence interval; OR = odds ratio

We observed a strong correlation between body A and body B dose-volume parameters when the volume was equal (e.g. body A and body B exposed to 5 Gy). It is easier to obtain the volume of body A than body B because body A is based on the body surface contour that can be acquired by auto-segmentation using commercially available software tools. Body A dose-volume parameters may be a convenient tool for predicting radiation-related lymphopenia.

Our data showed that there was no significant difference in the overall survival of patients with LP3+ and other grades of lymphopenia. Although lymphopenia related to curative chemoradiotherapy has been shown to be associated with poor patient outcomes11-18, its prognostic value for palliative RT remains to be determined.

Our study has some limitations. The study population was small and some useful predictors of lymphopenia may have gone undetected. Also, as our study was retrospective, laboratory data were acquired at different points after the start of RT. Consequently, the true nadir lymphocyte count may not have been evaluated in some patients.

In summary, we identified body A and body B dose-volume parameters were useful new predictors of radiation-related lymphopenia. These body dose-volume parameters were acquired by delineating the body surface and they may be convenient for predicting radiation-related lymphopenia. As the parameters are not organ-specific, they are applicable at various treatment sites. Although their predictive value for radiation-related lymphopenia should be examined in groups of patients with different diseases, our findings may help to elucidate the mechanisms underlying the elicitation of radiation-related lymphopenia in patients treated with palliative RT.

Delineation of the three organs at risk. Body A is the volume enclosed by the body surface contour. Body B excludes air, pleural effusion, ascites, bile, urine, and the intestinal content. BM = bone marrow.
Delineation of the three organs at risk. Body A is the volume enclosed by the body surface contour. Body B excludes air, pleural effusion, ascites, bile, urine, and the intestinal content. BM = bone marrow.

Overall survival according to the grade of radiationrelated lymphopenia.CI = confidence interval.
Overall survival according to the grade of radiationrelated lymphopenia.CI = confidence interval.

Patient and treatment characteristics (n = 54)

CharacteristicNo. of patients%
Patient characteristics
Male gender3361
Age (years)
 Median69
Range39-86
Primary tumor
 Lung1426
 Gastrointestinal917
 Skin47
 Liver36
 Uterus36
 Others

Others include head and neck (3 patients), breast (3 patients), mediastinal (3 patients), urogenita (8 patients), and soft tissue (4 patients) tumors;

2139
Previous radiotherapy1528
Previous chemotherapy2648
Concurrent steroid use2343
Bone metastasis2750
Brain metastasis1120
Interval from tumor diagnosis to radiotherapy (months)
 Median13
 Range0-168
Pre-radiotherapy absolute lymphocyte count (× 106/L)
 Median1356
 Range844-3468
Treatment characteristics
Total radiation dose (Gy)
 Median30
 Range16-50
Number of fractions
 Median10
 Range4-25
Fraction size (Gy)
 Median3
 Range2-5
Total monitor units for all fractions
 Median4433
 Range1896–13890
Total irradiation time for all fractions (minutes)
 Median7.5
 Range3.2-37.7
Treatment site
 Head and neck1426
 Chest2444
 Abdomen1019
 Pelvis1120
 Limb12
Splenic irradiation

Yes, if any part of the spleen was covered by the 5 Gy idodose line;

917
Thymic irradiation

Yes, if any part of the thymus was covered by the 5 Gy idodose line.

1528

Univariate logistic regression analysis for lymphopenia of grade 3 or higher

VariableOR95% CIp-value
Patient characteristics
Male vs. female1.390.46–4.220.55
Age (per 1 year increase)0.990.94–1.030.53
Previous radiotherapy (yes vs. no)1.020.30–3.470.98
Previous chemotherapy (yes vs. no)0.530.18–1.580.26
Concurrent steroid use (yes vs. no)1.070.36–3.170.91
Bone metastasis (yes vs. no)0.860.29–2.530.78
Brain metastasis (yes vs. no)0.720.18–2.840.64
Interval from tumor diagnosis to radiotherapy (per 1 month increase)1.000.99–1.020.81
Pre-radiotherapy absolute lymphocyte count (per increase of 1 × 106/l)0.990.99–1.000.23
Treatment characteristics
Total radiation dose (per 1-Gy increase)1.060.99–1.140.11
Number of fractions (per 1-fraction increase)1.181.01–1.380.036
Total monitor units over the entire treatment
course (per increase of 100 monitor units)1.010.99–1.030.29
Total irradiation time over the entire treatment course (per 1-minute increase)0.990.92–1.080.91
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line

6.341.18–34.240.032
Thymic irradiation (yes vs. no)

Yes, if any part of the thymus was covered by the 5 Gy idodose line.

0.580.17–2.030.39
Body A V5 (per 1 × 103 mL increase)1.551.06–2.260.025
Body A V10 (per 1 × 103 mL increase)1.601.04–2.450.032
Body A V20 (per 1 × 103 mL increase)1.600.96–2.680.074
Body A V30 (per 1 × 103 mL increase)1.870.95–3.680.069
Body B V5 (per 1 × 103 mL increase)1.581.05–2.380.027
Body B V10 (per 1 × 103 mL increase)1.631.04–2.560.035
Body B V20 (per 1 × 103 mL increase)1.590.94–2.720.087
Body B V30 (per 1 × 103 mL increase)1.840.93–3.670.082
BM V5 (per 1 × 103 mL increase)3.620.37–35.360.27
BM V10 (per 1 × 103 mL increase)2.880.27–31.100.38
BM V20 (per 1 × 103 mL increase)1.780.15–20.920.65
BM V30 (per 1 × 103 mL increase)4.730.19–115.780.34

Multivariate logistic regression analysis for lymphopenia of grade 3 or higher

VariableOR95% CIp-value
Body A V5 (per 1 × 103 mL increase)1.581.03–2.420.036
Number of fractions (per 1-fraction increase)1.261.03–1.530.027
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.120.74–35.280.098
Body A V10 (per 1 × 103 mL increase)1.681.04–2.700.034
Number of fractions (per 1-fraction increase)1.261.03–1.550.026
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.250.77–35.760.090
Body B V5 (per 1 × 103 mL increase)1.631.03–2.570.038
Number of fractions (per 1-fraction increase)1.251.03–1.530.028
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.460.79–37.530.085
Body B V10 (per 1 × 103 mL increase)1.721.04–2.870.036
Number of fractions (per 1-fraction increase)1.261.03–1.550.027
Splenic irradiation (yes vs. no)

Yes, if any part of the spleen was covered by the 5 Gy idodose line; Factors with p < 0.05 by univariate analysis (number of fractions and splenic irradiation) were taken into account to test the indep

5.590.82–37.990.078

Spearman correlation coefficients between the dose-volume parameters and the nadir lymphocyte count

Nadir lymphocyte count
Absolute lymphocyte count at nadirLymphocyte count ratio

The lymphocyte count ratio was calculated by dividing the nadir absolute lymphocyte count by the pre-radiotherapy absolute lymphocyte count.

VariableSpearman’s rhop-valueSpearman’s rhop-value
Body A V5-0.2650.053-0.3500.010
Body A V10-0.2830.038-0.3670.006
Body A V20-0.2310.093-0.2550.063
Body A V30-0.3050.025-0.2810.039
Body B V5-0.2740.045-0.3470.010
Body B V10-0.2800.040-0.3520.009
Body B V20-0.2360.086-0.2600.057
Body B V30-0.3020.027-0.2800.041
BM V5-0.1520.27-0.2100.13
BM V10-0.1610.25-0.2070.13
BM V20-0.1350.33-0.1610.25
BM V30-0.1680.23-0.1850.18

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-9.MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature201148048048910.1038/nature10673Search in Google Scholar

Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-80.HiraokaKMiyamotoMChoYSuzuokiMOshikiriTNakakuboYConcurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinomaBr J Cancer20069427528010.1038/sj.bjc.6602934Search in Google Scholar

Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7: 4.OhtaniHFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancerCancer Immun200774Search in Google Scholar

Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res 2011; 17: 4296-308.LohrJRatliffTHuppertzAGeYDictusCAhmadiREffector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-βClin Cancer Res2011174296430810.1158/1078-0432.CCR-10-2557Search in Google Scholar

Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123: 2873-92.Gu-TrantienCLoiSGaraudSEqueterCLibinMde WindACD4+ follicular helper T cell infiltration predicts breast cancer survivalJ Clin Invest20131232873289210.1172/JCI67428Search in Google Scholar

Le Scodan R, Massard C, Mouret-Fourme E, Guinebretierre JM, Cohen-Solal C, De Lalande B, et al. Brain metastases from breast carcinoma: Validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys 2007; 69: 839-45.Le ScodanRMassardCMouret-FourmeEGuinebretierreJMCohen-SolalCDe LalandeBBrain metastases from breast carcinoma: Validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic scoreInt J Radiat Oncol Biol Phys20076983984510.1016/j.ijrobp.2007.04.024Search in Google Scholar

Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: A biomarker for IL-2 immunotherapy. J Immunother 2003; 26: 394-402.FumagalliLAVinkeJHoffWYpmaEBrivioFNespoliALymphocyte counts independently predict overall survival in advanced cancer patients: A biomarker for IL-2 immunotherapyJ Immunother20032639440210.1097/00002371-200309000-00002Search in Google Scholar

De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, et al. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. J Geriatr Oncol 2014; 5: 156-63.De GiorgiURihawiKAietaMLo ReGSavaTMasiniCLymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancerJ Geriatr Oncol2014515616310.1016/j.jgo.2014.01.001Search in Google Scholar

Jin Y, Ye X, He C, Zhang B, Zhang Y. Pretreatment neutrophil-to-lymphocyte ratio as predictor of survival for patients with metastatic nasopharyngeal carcinoma. Head Neck 2015; 37: 69-75.JinYYeXHeCZhangBZhangYPretreatment neutrophil-to-lymphocyte ratio as predictor of survival for patients with metastatic nasopharyngeal carcinomaHead Neck201537697510.1002/hed.23565Search in Google Scholar

Feng J, Wang Z, Guo X, Chen Y, Cheng Y, Tang Y. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: A meta-analysis. Int J Hematol 2012; 95: 143-8.FengJWangZGuoXChenYChengYTangYPrognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: A meta-analysisInt J Hematol20129514314810.1007/s12185-011-0993-6Search in Google Scholar

Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest 2012; 30: 571-6.BalmanoukianAYeXHermanJLaheruDGrossmanSAThe association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreasCancer Invest20123057157610.3109/07357907.2012.700987Search in Google Scholar

Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 2015; 38: 259-65.WildATYeXEllsworthSGSmithJANarangAKGargTThe association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinomaAm J Clin Oncol20153825926510.1097/COC.0b013e3182940ff9Search in Google Scholar

Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2016; 94: 571-9.WildATHermanJMDholakiaASMoningiSLuYRosatiLMLymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancerInt J Radiat Oncol Biol Phys20169457157910.1016/j.ijrobp.2015.11.026Search in Google Scholar

Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 2014; 89: 1084-91.TangCLiaoZGomezDLevyLZhuangYGebremichaelRALymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomesInt J Radiat Oncol Biol Phys2014891084109110.1016/j.ijrobp.2014.04.025Search in Google Scholar

Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol 2016; 140: 76-82.WuESOduyeboTCobbLPCholakianDKongXFaderANLymphopenia and its association with survival in patients with locally advanced cervical cancerGynecol Oncol2016140768210.1016/j.ygyno.2015.11.013Search in Google Scholar

Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011; 17: 5473-80.GrossmanSAYeXLesserGSloanACarrawayHDesideriSImmunosuppression in patients with high-grade gliomas treated with radiation and temozolomideClin Cancer Res2011175473548010.1158/1078-0432.CCR-11-0774Search in Google Scholar

Mendez JS, Govindan A, Leong J, Gao F, Huang J, Campian JL. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol 2016; 127: 329-35.MendezJSGovindanALeongJGaoFHuangJCampianJLAssociation between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastomaJ Neurooncol201612732933510.1007/s11060-015-2037-1Search in Google Scholar

Cho O, Oh YT, Chun M, Noh OK, Hoe JS, Kim H. Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer. Head Neck 2016; 38 (Suppl 1): E1061-7.ChoOOhYTChunMNohOKHoeJSKimHMinimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancerHead Neck201638Suppl 1E1061E106710.1002/hed.24158Search in Google Scholar

Raben M, Walach N, Galili U, Schlesinger M. The effect of radiation therapy on lymphocyte subpopulations in cancer patients. Cancer 1976; 37: 141721.RabenMWalachNGaliliUSchlesingerMThe effect of radiation therapy on lymphocyte subpopulations in cancer patientsCancer1976371417142110.1002/1097-0142(197603)37:3<1417::AID-CNCR2820370324>3.0.CO;2-NSearch in Google Scholar

Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: Modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 2013; 31: 140-4.YovinoSKleinbergLGrossmanSANarayananMFordEThe etiology of treatment-related lymphopenia in patients with malignant gliomas: Modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cellsCancer Invest20133114014410.3109/07357907.2012.762780Search in Google Scholar

Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen OF, Fergus S, et al. Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys 2015; 92: 1000-7.HuangJDeWeesTABadiyanSNSpeirsCKMullenOFFergusSClinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade gliomaInt J Radiat Oncol Biol Phys2015921000100710.1016/j.ijrobp.2015.04.005Search in Google Scholar

Trowell OA. The sensitivity of lymphocytes to ionising radiation. J Pathol Bacteriol 1952; 64: 687-704.TrowellOAThe sensitivity of lymphocytes to ionising radiationJ Pathol Bacteriol19526468770410.1002/path.1700640403Search in Google Scholar

Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res 1990; 123: 224-7.NakamuraNKusunokiYAkiyamaMRadiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assayRadiat Res199012322422710.2307/3577549Search in Google Scholar

Campbell BA, Callahan J, Bressel M, Simoens N, Everitt S, Hofman MS, et al. Distribution atlas of proliferating bone marrow in non-small cell lung cancer patients measured by FLT-PET/CT imaging, with potential applicability in radiation therapy planning. Int J Radiat Oncol Biol Phys 2015; 92: 1035-43.CampbellBACallahanJBresselMSimoensNEverittSHofmanMSDistribution atlas of proliferating bone marrow in non-small cell lung cancer patients measured by FLT-PET/CT imaging, with potential applicability in radiation therapy planningInt J Radiat Oncol Biol Phys2015921035104310.1016/j.ijrobp.2015.04.027Search in Google Scholar

Campbell AC, Hersey P, MacLennan IC, Kay HE, Pike MC. Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J 1973; 2: 385-8.CampbellACHerseyPMacLennanICKayHEPikeMCImmunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemiaBr Med J1973238538810.1136/bmj.2.5863.385Search in Google Scholar

Weeke E. The development of lymphopenia in uremic patients undergoing extracorporeal irradiation of the blood with portable beta units. Radiat Res 1973; 56: 554-9.WeekeEThe development of lymphopenia in uremic patients undergoing extracorporeal irradiation of the blood with portable beta unitsRadiat Res19735655455910.2307/3573724Search in Google Scholar

Boehm T, Bleul CC. The evolutionary history of lymphoid organs. Nat Immunol 2007; 8: 131-5.BoehmTBleulCCThe evolutionary history of lymphoid organsNat Immunol2007813113510.1038/ni1435Search in Google Scholar

Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, Bianchi M, et al. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiother Oncol 2016; 118: 79-84.SiniCFiorinoCPernaLNoris ChiordaBDeantoniCLBianchiMDose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiationRadiother Oncol201611817918410.1016/j.radonc.2015.11.020Search in Google Scholar

MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer 1978; 41: 108-11.MacLennanICKayHEAnalysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiationCancer19784110811110.1002/1097-0142(197801)41:1<108::AID-CNCR2820410116>3.0.CO;2-ZSearch in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo